Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: CombiGene one step closer to clinical trials

In recent weeks, CombiGene has lined up several milestones on the way to the goal of initiating clinical trials in patients with drug-resistant focal epilepsy. The latest milestone was reached on September 28 when the company announced that it, together with the Spanish manufacturer Viralgen, will begin large-scale production of the primary drug candidate CG01 for future safety and biodistribution studies. CEO Jan Nilsson gave a brief comment to BioStock.Read the full interview with Jan Nilsson, CEO of CombiGene, at biostock.se : https://www.biostock.se/en/

Mekonomen Group recruits Geir Hoff as new Country Manager in Norway within the MECA / Mekonomen business area

Geir Hoff takes over as the new Country Manager in Norway within the business area MECA / Mekonomen after Torhild Barlaup. Geir has a distinguished experience within the Swedish retail chain Clas Ohlson, presently as Director of Country Operations, where he is part of Clas Ohlson's Group Management. Geir has also had the role as Director of New Markets and Expansion, as well as Country Manager and Marketing Manager for Clas Ohlson´s Norwegian market. “I am very glad about the recruitment of Geir Hoff to Mekonomen Group as Country Manager for Norway. Geir has extensive experience

Mentice entered into an agreement to acquires all substantial assets of the US medical technology company Vascular Simulations Inc.

Mentice AB (publ), a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures acquires the substantial assets from Vascular Simulation Inc (Vascular Simulation). The purchase price amounts to 5.6 million USD (approx. 48 million SEK) with a possible additional purchase price of maximum 0.4 million USD (approx. 3.5 million SEK). Purchase price will be paid with a directed new shares issue in Mentice AB. This acquisition will expand Mentice’s global leadership role in endovascular simulation by expanding its solutions

Barbro Fagerbakk has been appointed Chief Revenue Officer and a member of the Management Team of Avidly Plc

Barbro Fagerbakk has been appointed Chief Revenue Officer and a member of the Management Team of Avidly Plc Avidly Plc       Changes board/management/certified advisors             1 October 2020 at 11:00 am EET Barbro Fagerbakk (b. 1983) has been appointed Chief Revenue Officer (CRO) and a member of the Management Team of Avidly Plc as of 1 October 2020. Fagerbakk is the co-founder of Inbound Norway AS, which Avidly acquired in 2018. She currently works as Sales Director of Avidly Norway. As Avidly’s CRO she will be responsible for Avidly's revenue-generating activities and

Stayble's pre-clinical data and the clinical phase 1b study on STA363 is published in the journal SPINE

A scientific article based on pre-clinical studies and the clinical phase 1b study with STA363 has been published in the highly prestigious scientific journal Spine."It is crucial to have external validation of our research and pharmaceutical development. The publication of clinical study results in one of the most highly ranked journals within our field, Spine, reflects the high level of interest in STA363 and marks a milestone for the company," says Anders Lehmann, VP Development, Stayble. The scientific article presents Stayble's pre-clinical and early stage clinical research,

BIAL and Recipharm expand long-term supply agreement for opicapone API

Portuguese pharma company, BIAL, and global contract development and manufacturing organisation (CDMO), Recipharm, have expanded a long-term agreement for the global manufacturing and supply of BIAL’s proprietary molecule opicapone. The API being manufactured at Recipharm’s facility in Cramlington, UK is used to formulate BIAL’s Ongentys product, an adjunctive therapy used to treat patients with Parkinson’s disease. The expansion of the agreement with BIAL follows the successful market authorisation application for Japan in June with the product officially launching to the Japanese

The 200[th] patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020

Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the last visit of the 200[th] patient has taken place in Part A of the pivotal NeflgArd Phase 3 study.The NefIgArd trial is studying the effect of Nefecon versus placebo in patients with IgA nephropathy (IgAN) at approximately 150 sites in 19 countries. It has a substantially similar design to the successful Phase 2b NEFIGAN trial, the results of which were published in the Lancet in 2017. The first patient in NeflgArd was randomized in November 2018, and in December 2019 Calliditas announced the full recruitment of Part

Bioservo signs distribution agreement with Carl Stahl in Germany

Bioservo Technologies AB has signed a distribution agreement with Carl Stahl Hebetechnik GmbH for selling Ironhand[®] in Germany. Carl Stahl is one of the world market leaders in the field of rope and lifting technology and is represented in 70 locations on 4 continents. In the lifting technology division, Carl Stahl, in cooperation with partners, offers a complete range of high-quality products and customer-specific workplace solutions for the safe and efficient transport of goods. Products and solutions from Carl Stahl Hebetechnik improve the production processes in companies and

Minutes of the Monetary Policy Meeting held on 21 September 2020

At the Monetary Policy Meeting on 21 September, the Executive Board of the Riksbank decided to hold the repo rate unchanged at zero per cent. The Riksbank’s zero policy rate and extensive programme of measures are providing continued support to economic developments and helping inflation rise towards the target.The coronavirus pandemic has dominated developments in the global economy over the past six months. In the first acute phase in the spring, many countries were hit by sharp falls in GDP, rising unemployment and turmoil on financial markets. The members noted that the measures taken

First Episealer® surgery performed in the US

Episurf Medical (NASDAQ: EPIS B) today announces that the first Episealer® surgery in the US was performed yesterday. The surgery was performed by Dr. Doug Haltom, MD at the West Tennessee Bone & Joint Clinic in Jackson, Tennessee (Clinical Research Solutions, Jackson, TN), within the company's IDE Clinical Trial, EPIC-Knee: Episealer® Knee System IDE Clinical Study. “The procedure went great today. Instrumentation worked extremely well. Excited about the future of this product and procedure” says Dr. Doug Haltom. "This is, of course, a great milestone for us, and we would like to

Aker BioMarine opens new warehouse in India to meet growing demand for QRILL products

Aker BioMarine continues to invest in India by establishing a new distribution hub in Chennai, to keep the region well-stocked with its QRILL Aqua products.After first entering the Indian market in 2018, when Aker BioMarine India was established in Mumbai, the company has experienced growing demand for its products. The new Chennai warehouse will strengthen local presence in India while also enabling the company to serve its customers across the region with its nutrient-rich, krill-based ingredients for fish and shrimp feeds. “India is one of the world’s largest shrimp markets, which

Conotoxia introduces its own custom typeface

Following in the footsteps of the world's technological giants, Conotoxia now has its typeface, adding an essential piece of the puzzle to the brand's visual identification.The Conotoxia font, created especially for the fintech's use, will be adopted on the company's website, mobile apps, and marketing materials. The design process took almost a year. It reflects the brand's personality and distinguishes it from the competitors. Apart from visual branding and image consistency, there are also more down to earth motives to have a custom typeface. Published content must be easy to read,

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 60 -1 OCTOBER 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, Motortramp A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tel.: +45 3273 0624

Human rights defenders from Iran and Belarus among 2020 Right Livelihood Laureates

STOCKHOLM - Imprisoned Iranian human rights lawyer Nasrin Sotoudeh, US civil rights lawyer Bryan Stevenson, indigenous rights and environmental activist Lottie Cunningham Wren of Nicaragua, and Belarusian pro-democracy activist Ales Bialiatski and the non-governmental organisation Human Rights Centre “Viasna” have been selected as the 2020 Right Livelihood Laureates , the Swedish Right Livelihood Foundation said on Thursday.The Right Livelihood Award , widely known as the “Alternative Nobel Prize,”

Wärtsilä to divest its Valves business

Wärtsilä Corporation, Press release, 1 October 2020 at 10:00 AM EESTThe technology group Wärtsilä announces the divestment of 100% of the shares in Wärtsilä Valves Ltd to an affiliate of Evergreen Capital L.P., based in New York, US.  Wärtsilä Valves Ltd. supplies the entire range of three long-established brands: Shipham, John Mills and Robert Cort. Its activities include engineering, assembly, testing, sales and delivery of nickel aluminium bronze (NAB) and duplex valves for marine, oil & gas and energy markets. Additionally, Wärtsilä Valves offers applications for Valves’ products,

Telenor Connexion and Ericsson enable sustainable micro-factories with IoT Accelerator

· Powered by Ericsson IoT Accelerator, Telenor Connexion provides global connectivity to Wayout's sustainable micro-factories · Telenor Connexion to deliver cellular IoT connectivity management services, SIM cards and agreements with local operators · Ericsson IoT Accelerator enables cost-efficient IoT connectivity management and operations using the secure, scalable and standardized worldwide mobile network infrastructurePowered by Ericsson (NASDAQ: ERIC) IoT Accelerator, Telenor Connexion will provide global connectivity to Wayout's sustainable micro-factories starting in East

Planetcon Oy become part of Rejlers Finland

Rejlers Finland has strengthened its building services expertise and acquired the entire share capital of Planetcon Oy on October 1, 2020. As a result of the share transaction, Planetcon will become a subsidiary of Rejlers business area Buildings, Rejlers PM Building Technology.Planetcon Oy has approximately 20 employees, was founded in the year 2000 in Jyväskylä and specializes in building technology, expert- and developer services. ”Rejlers building technology design expertise and experience deepen Planetcon's expertise in building technology construction and expert services. At the

BioStock: Scandion Oncology strengthens executive leadership

As its clinical development program intensifies, Scandion Oncology can start planning for its next phase of the company development and clinical trials of its top candidate, SCO-101, in metastatic colorectal cancer. This means the company is ready to transition into its next phase of development, and it took a major step in that direction by appointing Bo Rode Hansen to the position of CEO. BioStock reached out to the new CEO to learn more about what’s in store for Scandion Oncology in the months to come.Read the full interview with Bo Rode Hansen, CEO of Scandion Oncology, at biostock.se (

INVISIO launches the first headset that performs in all mission scenarios

INVISIO today launches a new innovative over-the-ear headset – the INVISIO T7. The tactical communication headset sets new standards for submersibility, ruggedness, flexibility, and comfort while combining industry-leading hearing protection with situational awareness. INVISIO has for many years led the market in advanced in-ear hearing protection headsets with situational awareness. The T7 headset extends that leadership to over-the-ear devices, combining the best of INVISIOs capabilities in tactical communication headsets. Designed for military and public safety professionals on

YIT starts planning to close down its Infrastructure business in Norway

YIT Corporation   Investor News     1 October 2020 at 9:45 a.m.YIT starts planning to close down its Infrastructure operations in Norway. The business in Norway scaled substantially down as a result of the sale of the Nordic paving and mineral aggregates businesses on 1 April 2020, and the outlook for the remaining Infrastructure business is weak. The potential exit from Norway is in line with YIT’s strategy to increase capital efficiency and to scale down operations which do not bring significant synergies or in which profitability does not meet the targets set. YIT will initiate co-

Airtours chooses Wallenstam and Birger Jarlsgatan 64

At Birger Jarlsgatan 64 in Stockholm, in the same property as Wallenstam’s Stockholm office, Sweden’s fourth largest tour operator Airtours is now moving into the fifth floor. This is a strategic choice as the business and all sales have been adapted to the fact that all trips are now arranged online and with personal service by telephone.“We have seen that our customers’ need for a physical store has almost completely disappeared so a move to a new premises without retail space feels totally natural,” says Stefan Chatzopoulos, Public Relations Manager at Airtours. Airtours was founded

Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.

According to schedule, 2cureX’s clinical partner University Hospital Vejle today enrolled the last patient in the clinical validation study TICC1. In this interventional study, IndiTreat® test results guide the drug treatment of patients with metastatic colorectal cancer who have exhausted guideline-based treatment options.The TICC1 clinical trial (Clinicaltrials.gov no. NCT03251612) was launched end 2017 with the purpose of evaluating IndiTreat’s ability to successfully guide the drug therapy of end-stage metastatic colorectal cancer patients. As planned in the trial protocol, 45 patients

Digital solutions with potential to transform service within the rail industry

With the digital transformation of the rail industry, follows an increased demand for up-to-date service and maintenance information. By making sure service technicians get appropriate training and have access to the latest technical documentation, the cost of downtime can be reduced. Semcon is aiming to grow its business within rail as the demand for new service solutions is rapidly increasing.“At Semcon we see great potential for growth by providing digital documentation and training solutions for the rail industry. Today, we are one of the leading suppliers of product information to a

Subaru Selects Veoneer to Manufacture New Generation EyeSight

Stockholm, Sweden, October 1, 2020: The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), has partnered with Subaru to introduce the new generation EyeSight on the all-new Subaru Levorg.  Veoneer will begin producing systems for the Japan market starting later this year.Veoneer was selected by Subaru due to its experience in stereo vision systems and opto-mechanical design capabilities. This business is included in Veoneer’s previously announced backlog.  The new generation EyeSight hardware is a variant of Veoneer’s 4[th] generation stereo vision system, re-

There are no items matching the current filter
There are no more items matching the current filter
Back to top